LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that Linda Marbán, Ph.D., Capricor president and CEO, will provide a presentation on exosomes at the plenary session of the International Society for Cellular Therapy (ISCT) 2018 Montreal Annual Meeting on Friday, May 4. Dr. Marbán, will also chair a plenary breakout session on Pre-Clinical Application of Exosomes later the same day, which will feature top-scoring abstracts and invited speakers.
ISCT 2018 Montreal Annual Meeting
| Date of presentations: Friday, May 4, 2018 | |||
| Plenary session time: 8:45 a.m. to 10:15 a.m. ET | |||
| Plenary breakout session time: 3:30 p.m. to 5 p.m. ET |
In addition, Capricor will be delivering abstract and poster presentations during the meeting: These presentations are: “Cardiosphere-Derived Cells (CDCs) show Strong Immunomodulatory Activity and Improve Muscle Physiology when Systemically Delivered in a DMD Mouse Model” and “Extracellular Vesicles from CDCs and from Mesenchymal Stem Cells (MSCs) Show different Immunomodulatory capabilities and Distinct RNA Cargo.”
“The presentations show systemic delivery of allogeneic CDCs improve exercise capability in a mouse model of Duchenne muscular dystrophy and highlight the mechanisms of action in Capricor’s pipeline therapies to treat diseases of inflammation and fibrosis,” Dr. Marbán said. “The data support our assertions that CDC exosomes are different from MSC exosomes – that CDC exosomes are packed with specific RNAs and proteins, which drive their potency in treating inflammation and fibrosis.”
The poster presented at ISCT will be available on the Events & Presentations section of Capricor's website after they’re presented at the conference.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic biologic that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. For more information, visit www.capricor.com.
Keep up with Capricor on social media: www.facebook.com/capricortherapeutics, www.instagram.com/capricortherapeutics/ and https://twitter.com/capricor
About ISCT
ISCT is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. ISCT is the only group focused on pre-clinical and translational aspects of developing cell therapy products. As such, ISCT helps academic, government and biotech/pharma sectors transform research into practice and product. ISCT is incorporated as a not-for-profit organization, 501(c)(3) in Washington, DC. For more information, visit http://www.celltherapysociety.org/
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a devastating genetic disorder that causes muscle degeneration and leads to death, generally before the age of 30, most commonly from heart failure. It occurs in one in every 3,600 live male births across all races, cultures and countries. Duchenne muscular dystrophy afflicts approximately 200,000 boys and young men around the world. Treatment options are limited, and there is no cure.
About CAP-1002
CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that contains cardiac progenitor cells. CAP-1002 has been shown to exert potent immunomodulatory activity and stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. Capricor has secured Food and Drug Administration designations that will expedite the review of CAP-1002, including the Orphan Drug Designation and Regenerative Medicine Advanced Therapy designation.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on March 22, 2018, in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015, together with the prospectus included therein and prospectus supplements thereto. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. CAP-2003 has not yet been approved for clinical investigation.